Drug to be tested on patients with rare endocrine disorder
Ann Arbor-basedMillendo Therapeutics Inc.has begun Phase 2U.S. Food and DrugAdministrationtrials at theUniversity ofMichigan Health Systemof a drug candidate called ATR-101 on patients with classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine disorder characterized by overgrowth of the adrenal glands.
The trial, which will eventually involve 15-20 patients at six or seven medical centers around the U.S., will evaluate safety, efficacy and effective dosing levels.
CAH can lead to severe virilization in females, testicular tumors in men and infertility.
ATR-101 is also being studied in a Phase 1 clinical trial in patients with adrenocortical carcinoma.